Accelerated aging of the putamen in patients with major depressive disorder

Accelerated aging of the putamen in patients with major depressive disorder

PDF | Appendix

J Psychiatry Neurosci 2017;42(3):164-171

Matthew D. Sacchet, PhD; M. Catalina Camacho, BA; Emily E. Livermore, BA; Ewart A.C. Thomas, PhD; Ian H. Gotlib, PhD

Abstract

Background: Growing evidence indicates that major depressive disorder (MDD) is characterized by accelerated biological aging, including greater age-related changes in physiological functioning. The disorder is also associated with abnormal neural reward circuitry, particularly in the basal ganglia (BG). Here we assessed age-related changes in BG volume in both patients with MDD and healthy control participants.

Methods: We obtained whole-brain T1-weighted images from patients with MDD and healthy controls. We estimated grey matter volumes of the BG, including the nucleus accumbens, caudate, pallidum and putamen. Volumes were assessed using multivariate analysis of covariance (MANCOVA) with age as a covariate, followed by appropriate post hoc tests.

Results: We included 232 individuals (116 patients with MDD) in our analysis. The MANCOVA yielded a significant group × age interaction (p = 0.043). Analyses for each region yielded a significant group × age interaction in the putamen (univariate test, p = 0.005; permutation test, p = 0.004); this effect was not significant in the other regions. The negative association between age and putamen volume was twice as large in the MDD than in the control group (–35.2 v. –16.7 mm3/yr), indicating greater age-related volumetric decreases in the putamen in individuals with MDD than in controls.

Limitations: These findings are cross-sectional; future studies should assess the longitudinal impact of accelerated aging on anhedonia and neural indices of reward processing.

Conclusion: Our results indicate that putamen aging is accelerated in patients with MDD. Thus, the putamen may uniquely contribute to the adverse long-term effects of depressive psychopathology and may be a useful target for the treatment of MDD across the lifespan.


Submitted Jan. 19, 2016; Revised June 22, 2016; Revised Aug. 6, 2016; Accepted Aug. 7, 2016; Early-released Oct. 18, 2016

Acknowledgements: This study was supported by National Science Foundation Integrative Graduate Education and Research Traineeship (NSF IGERT) Recipient Award 0801700 and National Science Foundation Graduate Research Fellowship Program (NSF GRFP) DGE-1147470 awarded to M. Sacchet, and by a National Institute of Mental Health Grant MH59259 awarded to I. Gotlib.

Affiliations: From the Department of Psychology, Stanford University, Stanford, Calif., USA (Sacchet, Camacho, Livermore, Thomas, Gotlib); the Neurosciences Program, Stanford University, Stanford, Calif., USA (Sacchet, Gotlib); and Palo Alto University, Palo Alto, Calif., USA (Sacchet, Livermore).

Competing interests: None declared.

Contributors: M. Sacchet and I. Gotlib designed the study. M. Sacchet, M. Camacho, E. Livermore and I. Gotlib acquired the data, which M. Sacchet, M. Camacho, E. Thomas and I. Gotlib analyzed. M. Sacchet, M. Camacho and I. Gotlib wrote the article, which all authors reviewed and approved for publication.

DOI: 10.1503/jpn.160010

Correspondence to: M.D. Sacchet, Department of Psychology, Jordan Hall, Building 01-420, Stanford University, 450 Serra Mall, Stanford,
CA, USA; msacchet@stanford.edu